The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  D. Fan,et al.  CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3 , 2021, Theranostics.

[3]  Fenghua Wang,et al.  The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors , 2020, Molecular cancer.

[4]  Y. Bang,et al.  Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. , 2020, JAMA oncology.

[5]  M. Xue,et al.  Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC) , 2020, Journal of experimental & clinical cancer research : CR.

[6]  Chen Huang,et al.  Circular RNA circCCDC9 acts as a miR-6792-3p sponge to suppress the progression of gastric cancer through regulating CAV1 expression , 2020, Molecular Cancer.

[7]  Chuanyuan Wei,et al.  Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p/CXCL12 axis in melanoma , 2020, Molecular Cancer.

[8]  Baoguang Hu,et al.  Epithelial‐mesenchymal transition may be involved in the immune evasion of circulating gastric tumor cells via downregulation of ULBP1 , 2020, Cancer medicine.

[9]  V. Pillarisetty,et al.  The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies. , 2019, Seminars in cancer biology.

[10]  Chang-ming Huang,et al.  Circular RNA circ-RanGAP1 regulates VEGFA expression by targeting miR-877-3p to facilitate gastric cancer invasion and metastasis. , 2019, Cancer letters.

[11]  V. Patel,et al.  The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[12]  C. Lawrie,et al.  CircRNAs and cancer: Biomarkers and master regulators. , 2019, Seminars in cancer biology.

[13]  W. Jia,et al.  A circRNA signature predicts postoperative recurrence in stage II/III colon cancer , 2019, EMBO molecular medicine.

[14]  Y. Jiang,et al.  Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Tianxin Lin,et al.  Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis , 2019, Molecular Cancer.

[16]  A. Sluder,et al.  Dual blockade of CXCL12‐CXCR4 and PD‐1–PD‐L1 pathways prolongs survival of ovarian tumor–bearing mice by prevention of immunosuppression in the tumor microenvironment , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  Weiwei Tang,et al.  CircPSMC3 suppresses the proliferation and metastasis of gastric cancer by acting as a competitive endogenous RNA through sponging miR-296-5p , 2019, Molecular Cancer.

[18]  S. Ge,et al.  The novel roles of circRNAs in human cancer , 2019, Molecular Cancer.

[19]  Tianxin Lin,et al.  Circular RNA circUBXN7 represses cell growth and invasion by sponging miR-1247-3p to enhance B4GALT3 expression in bladder cancer , 2018, Aging.

[20]  P. Ascierto,et al.  CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Van Cutsem,et al.  Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Joon-Oh Park,et al.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer , 2018, Nature Medicine.

[23]  Z. Zeng,et al.  Circular RNAs (circRNAs) in cancer. , 2018, Cancer letters.

[24]  Kazuhiro Yoshida,et al.  Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial , 2018, The Lancet.

[25]  M. Smid,et al.  Epithelial-Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression. , 2018, Cancer research.

[26]  N. Matsumura,et al.  Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation , 2018, Nature Communications.

[27]  A. Vanoli,et al.  EBV+ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8+ Intratumoral Lymphocytes , 2018, Cancers.

[28]  T. Yoshikawa,et al.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[29]  Fenghua Wang,et al.  Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression , 2017, Theranostics.

[30]  C. Qian,et al.  Circular RNA circMTO1 acts as the sponge of microRNA‐9 to suppress hepatocellular carcinoma progression , 2017, Hepatology.

[31]  Huidong Shi,et al.  The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion , 2017, Journal of the National Cancer Institute.

[32]  Laising Yen,et al.  Noncoding Effects of Circular RNA CCDC66 Promote Colon Cancer Growth and Metastasis. , 2017, Cancer research.

[33]  Li Yang,et al.  Increased complexity of circRNA expression during species evolution , 2017, RNA biology.

[34]  J. Yun,et al.  Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. , 2016, Cancer letters.

[35]  J. Kjems,et al.  The emerging landscape of circular RNA in life processes , 2016, RNA biology.

[36]  S. Spranger.  Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. , 2016, International immunology.

[37]  M. Dinger,et al.  Endogenous microRNA sponges: evidence and controversy , 2016, Nature Reviews Genetics.

[38]  Ling-Ling Chen.  The biogenesis and emerging roles of circular RNAs , 2016, Nature Reviews Molecular Cell Biology.

[39]  A. Azmi,et al.  Immune evasion in cancer: Mechanistic basis and therapeutic strategies. , 2015, Seminars in cancer biology.

[40]  Y. Sakamoto,et al.  CXCL12/CXCR4 activation by cancer‐associated fibroblasts promotes integrin β1 clustering and invasiveness in gastric cancer , 2015, International journal of cancer.

[41]  Haimin Li,et al.  Circular RNA: A new star of noncoding RNAs. , 2015, Cancer letters.

[42]  Trees-Juen Chuang,et al.  Biogenesis, identification, and function of exonic circular RNAs , 2015, Wiley interdisciplinary reviews. RNA.

[43]  Annie A Wu,et al.  Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells , 2015, Oncoimmunology.

[44]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[45]  G. Shan,et al.  Exon-intron circular RNAs regulate transcription in the nucleus , 2015, Nature Structural &Molecular Biology.

[46]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[47]  Peng Huang,et al.  Identification of MicroRNA‐214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression , 2014, Hepatology.

[48]  N. Sharpless,et al.  Detecting and characterizing circular RNAs , 2014, Nature Biotechnology.

[49]  Shanshan Zhu,et al.  Circular intronic long noncoding RNAs. , 2013, Molecular cell.

[50]  Fenghua Wang,et al.  Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer , 2012, Carcinogenesis.